On Monday, Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)’s shares declined -9.21% to $3.35.
Catalyst Pharmaceutical Partners, Inc. (CPRX) plan to seek approval and market a drug for a rare muscle-wasting disease is in jeopardy following the surprise disclosure Thursday of positive clinical trial results from a similar, competitive drug.
Privately held Jacobus Pharmaceuticals presented a poster Thursday at the American Academy of Neurology annual meeting showing “unequivocal evidence” that 3,4 Dap, the company’s experimental drug, is an effective treatment for patients with Lambert-Eaton Myasthenic Syndrome (LEMS).
Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs targeting rare (orphan) neurological diseases and disorders.
Amicus Therapeutics, Inc. (NASDAQ:FOLD)’s shares dropped -9.06% to $11.14.
Amicus Therapeutics, Inc. (FOLD) has designated David Allsop as Senior Vice President, International, effective recently. He will be responsible for Amicus’ international organizational build out, and will lead international commercial and market access activities for migalastat monotherapy for Fabry disease. Mr. Allsop will serve as a member of the Amicus executive team reporting to Bradley L. Campbell, President and Chief Operating Officer.
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its product candidate is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
At the end of Monday’s trade, Kite Pharma Inc (NASDAQ:KITE)‘s shares dipped -9.01% to $55.12.
Kite Pharma Inc (KITE) declared that Owen Witte, M.D., director of the Eli & Edythe Broad Center of Regenerative Medicine & Stem Cell Research at UCLA, is being honored at this year’s AACR conference as he receives the prestigious G.H.A. Clowes Memorial Award. In addition, Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery at the National Cancer Institute (NCI), has been inducted into the 2015 Class of Fellows of the AACR Academy. Dr. Witte is a scientific founder of Kite Pharma, serving on Kite’s Scientific Advisory Board, and Dr. Rosenberg is a special advisor to Kite.
Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products.
Emerge Energy Services LP (NYSE:EMES), ended its Monday’s trading session with -8.96% loss, and closed at $40.65.
Emerge Energy Services LP (EMES) declared that the board of directors of its general partner has declared a cash distribution of $1.00 for the first quarter of 2015. This distribution represents a 29% decrease contrast to the fourth quarter 2014 distribution of $1.41 per unit and a 12% decrease contrast to the first quarter 2014 distribution of $1.13 per unit. The distribution will be paid on May 14, 2015 to all unitholders of record as of May 6, 2015.
Emerge Energy Services LP acquires, owns, operates, and develops a portfolio of energy service assets in the United States. The company operates in two segments, Sand and Fuel. The Sand segment is involved in the production and sale of various grades of industrial sand primarily used in the extraction of oil and natural gas, in addition to in the production of building products and foundry materials.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
